Bortezomib‐containing induction regimens in transplant‐eligible myeloma patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|119|23|4119-4128

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.23, 2013-12, pp. : 4119-4128

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

LDH is an adverse prognostic factor independent of ISS in transplant‐eligible myeloma patients receiving bortezomib‐based induction regimens

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 4, 2015-04 ,pp. : 330-335

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib-Containing Regimens Are Effective in Multiple Myeloma - Results of a Non-Interventional Phase IV Study

By  

Oncology Research and Treatment, Vol. 38, Iss. 4, 2015-03 ,pp. : 167-173

Karger

Access to resources Recommend Favorite

Bortezomib, Thalidomide, and Dexamethasone (VTD) Induction Results in Better Overall Survival than Adriamycin, Thalidomide, and Dexamethasone (ATD) Induction in Previously Untreated Myeloma Patients Eligible for Transplants

By  

Acta Haematologica, Vol. 137, Iss. 4, 2017-05 ,pp. : 207-208

Karger

Access to resources Recommend Favorite

Bortezomib Administered Subcutaneously Is Well Tolerated in Bortezomib-Based Combination Regimens Used in Patients with Multiple Myeloma

By  

Oncology, Vol. 85, Iss. 4, 2013-09 ,pp. : 223-227

Karger

Access to resources Recommend Favorite

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 35-39

Karger

Access to resources Recommend Favorite